| 22.92 0.82 (3.71%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 27.03 | 1-year : | 31.58 |
| Resists | First : | 23.14 | Second : | 27.03 |
| Pivot price | 21.53 |
|||
| Supports | First : | 18.66 | Second : | 15.89 |
| MAs | MA(5) : | 22.07 |
MA(20) : | 20.73 |
| MA(100) : | 15.84 |
MA(250) : | 15.42 |
|
| MACD | MACD : | 1.3 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 87.5 |
D(3) : | 83.3 |
| RSI | RSI(14): 65.4 |
|||
| 52-week | High : | 23.14 | Low : | 9.95 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ADPT ] has closed below upper band by 3.4%. Bollinger Bands are 12.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 23.04 - 23.15 | 23.15 - 23.25 |
| Low: | 21.09 - 21.21 | 21.21 - 21.33 |
| Close: | 22.71 - 22.91 | 22.91 - 23.1 |
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Fri, 17 Jul 2026
Is Adaptive Biotechnologies (ADPT) Below Fair Value Or Too Pricey On Sales? - simplywall.st
Fri, 17 Jul 2026
Adaptive Biotechnologies CPO Lo reports $2.39m stock sale By Investing.com - Investing.com South Africa
Fri, 17 Jul 2026
Adaptive Biotechnologies Corp (ADPT) officer exercises 105,762 options and sells 105,762 shares - Stock Titan
Thu, 16 Jul 2026
Planned 5,000-share stock sale for ADPT (NASDAQ: ADPT) - Stock Titan
Sun, 12 Jul 2026
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run - The Motley Fool
Sat, 11 Jul 2026
What Message Do Insider Sales Send About Adaptive Biotechnologies (ADPT) - Kavout | AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 160 (M) |
| Shares Float | 125 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 96.4 (%) |
| Shares Short | 11,350 (K) |
| Shares Short P.Month | 8,240 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.36 |
| Profit Margin | -16.9 % |
| Operating Margin | -27.2 % |
| Return on Assets (ttm) | -5.8 % |
| Return on Equity (ttm) | -24 % |
| Qtrly Rev. Growth | 35 % |
| Gross Profit (p.s.) | 0.8 |
| Sales Per Share | 1.84 |
| EBITDA (p.s.) | -0.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | 16 (M) |
| PE Ratio | -73.94 |
| PEG Ratio | 0 |
| Price to Book value | 16.85 |
| Price to Sales | 12.41 |
| Price to Cash Flow | -135.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|